Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies

References

• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705. doi:10.3748/wjg.v22.i44.9694.
   PubMed Web of Science ®Google Scholar
• Akce M, Zaidi MY, Waller EK, et al. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 2018;9:2166. doi:10.3389/fimmu.2018.02166.
   PubMed Web of Science ®Google Scholar
• Miliotou AN, Papadopoulou LC. CAR T-cell therapy: A new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5–18. doi:10.2174/1389201019666180418095526.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024.
   PubMed Web of Science ®Google Scholar
• Townsend MH, Shrestha G, Robison RA, et al. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 2018;37(1):163. doi:10.1186/s13046-018-0817-0.
   PubMedGoogle Scholar
• Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151–155. doi:10.1097/PPO.0000000000000032.
   PubMed Web of Science ®Google Scholar
• Moher D, PRISMA Group, Liberati A, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7):1–18. doi:10.1172/jci.insight.99573.
   Web of Science ®Google Scholar
• Sun Q, Zhou S, Zhao J, et al. Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer. Oncotarget. 2018;9(17):13694–13705. doi:10.18632/oncotarget.24122.
   PubMedGoogle Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144. doi:10.1172/JCI83092.
   PubMed Web of Science ®Google Scholar
• Mohammed S, Sukumaran S, Bajgain P, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249–258. doi:10.1016/j.ymthe.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Abate-Daga D, Lagisetty KH, Tran E, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014;25(12):1003–1012. doi:10.1089/hum.2013.209.
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Ramachandran M, Leja J, et al. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer. 2014;14:30. doi:10.1186/1471-2407-14-30.
   PubMed Web of Science ®Google Scholar
• Anurathapan U, Chan RC, Hindi HF, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(3):623–633. doi:10.1038/mt.2013.262.
   PubMed Web of Science ®Google Scholar
• Yazdanifar M, Zhou R, Grover P, et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells. 2019;8(9):1–27. doi:10.3390/cells8091070.
   Web of Science ®Google Scholar
• Sukumaran S, Watanabe N, Bajgain P, et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 2018;8(8):972–987. doi:10.1158/2159-8290.CD-17-1298.
   PubMed Web of Science ®Google Scholar
• Zhang E, Yang P, Gu J, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102. doi:10.1186/s13045-018-0646-9.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hahn O, Rappl G, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology. 2012;143(4):1095–1107. doi:10.1053/j.gastro.2012.06.037.
   PubMed Web of Science ®Google Scholar
• Posey AD, Jr., Schwab RD, Boesteanu AC, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444–1454. doi:10.1016/j.immuni.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Raj D, Yang MH, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68(6):1052–1064. doi:10.1136/gutjnl-2018-316595.
   PubMed Web of Science ®Google Scholar
• Maliar A, Servais C, Waks T, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology. 2012;143(5):1375–1384. doi:10.1053/j.gastro.2012.07.017.
   PubMed Web of Science ®Google Scholar
• Smith TT, Moffett HF, Stephan SB, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127(6):2176–2191. doi:10.1172/JCI87624.
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Berahovich R, Zhou H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers. 2017;9(12):139. doi:10.3390/cancers9100139.
   PubMedGoogle Scholar
• Zhou X, Li J, Wang Z, et al. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia. 2013;15(5):544–553. doi:10.1593/neo.13168.
   PubMed Web of Science ®Google Scholar
• Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43doi:10.1186/1471-2288-14-43.
   PubMed Web of Science ®Google Scholar
• Berkey CS, Hoaglin DC, Mosteller F, et al. A random-effects regression model for meta-analysis. Stat Med. 1995;14(4):395–411. doi:10.1002/sim.4780140406.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7(3):177–188. doi:10.1016/0197-2456(86)90046-2.
   PubMedGoogle Scholar
• Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Statist. 1950;21(4):607–611. doi:10.1214/aoms/1177729756.
   Google Scholar
• Higgins JTJ, Chandler J, Cumpston M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6. Cochrane. 2019. www.training.cochrane.org/handbook.
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224–228. doi:10.1136/bmj.323.7306.224.
   PubMedGoogle Scholar
• Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320(7249):1574–1577. doi:10.1136/bmj.320.7249.1574.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155.
   PubMed Web of Science ®Google Scholar
• Tran E, Longo DL, Urba WJ. A milestone for CAR T cells. N Engl J Med. 2017;377(26):2593–2596. doi:10.1056/NEJMe1714680.
   PubMed Web of Science ®Google Scholar
• Wang MC, Papsidero LD, Kuriyama M, et al. Prostate antigen: a new potential marker for prostatic cancer. Prostate. 1981;2(1):89–96. doi:10.1002/pros.2990020109.
   PubMed Web of Science ®Google Scholar
• Katari UL, Keirnan JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011;13(9):643–650. doi:10.1111/j.1477-2574.2011.00344.x.
   PubMed Web of Science ®Google Scholar
• Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Onc. 2004;2(1):13. [Mismatch] doi:10.1186/1477-7819-2-13.
   PubMedGoogle Scholar
• Schepisi G, Cursano MC, Casadei C, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer. 2019;7(1):258. doi:10.1186/s40425-019-0741-7.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: Challenges to bench-to-bedside efficacy. J Immunol. 2018;200(2):459–468. doi:10.4049/jimmunol.1701155.
   PubMed Web of Science ®Google Scholar
• O'Hara M, Stashwick C, Haas AR, et al. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy. 2016;8(4):449–460. doi:10.2217/imt.16.4.
   PubMed Web of Science ®Google Scholar
• Zhang E, Gu J, Xue J, et al. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018;11(1):44doi:10.1186/s13045-018-0591-7.
   PubMedGoogle Scholar
• Jalali Nadoushan MR, Taheri T, Jouian N, et al. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urol J. 2007;4(3):151–154.
   PubMedGoogle Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, et al. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–567. doi:10.1038/nrc3770.
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PloS One. 2015;10(6):e0131242. doi:10.1371/journal.pone.0131242.
   PubMed Web of Science ®Google Scholar
• Kannagi R, Sakuma K, Miyazaki K, et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010;101(3):586–593. doi:10.1111/j.1349-7006.2009.01455.x.
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdanifar M, Roy LD, et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149.
   PubMed Web of Science ®Google Scholar
• Chaika NV, Gebregiworgis T, Lewallen ME, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci USA. 2012;109(34):13787–13792. doi:10.1073/pnas.1203339109.
   PubMed Web of Science ®Google Scholar
• Yuen A, Díaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl). 2014;2:91–106. doi:10.2147/HP.S52636.
   PubMedGoogle Scholar
• van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015;6:34. doi:10.3389/fimmu.2015.00034.
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol. 2008;181(11):7660–7669. doi:10.4049/jimmunol.181.11.7660.
   PubMed Web of Science ®Google Scholar
• Pang LY, Hurst EA, Argyle DJ. Cyclooxygenase-2: A role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int. 2016;2016:2048731. doi:10.1155/2016/2048731.
   PubMed Web of Science ®Google Scholar
• Fujihara S, Mori H, Kobara H, et al. Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(2):130–137. doi:10.2174/1872214811307020006.
   PubMedGoogle Scholar
• Sobolewski C, Cerella C, Dicato M, et al. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:215158. doi:10.1155/2010/215158.
   PubMedGoogle Scholar
• Yazdanifar M, Zhou R, Grover P, et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1 CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells. 2019;8(9):1070.
   Web of Science ®Google Scholar
• Caratelli S, Sconocchia T, Arriga R, et al. FCγ chimeric receptor-engineered T cells: methodology, advantages, limitations, and clinical relevance. Front Immunol. 2017;8:457. doi:10.3389/fimmu.2017.00457.
   PubMed Web of Science ®Google Scholar
• Rataj F, Jacobi SJ, Stoiber S, et al. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. Br J Cancer. 2019;120(1):79–87. doi:10.1038/s41416-018-0341-1.
   PubMed Web of Science ®Google Scholar
• Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res. 2019;9(2):228–241.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018.
   PubMed Web of Science ®Google Scholar